Dr. James K. Mangan, MD

Dr. Mangan practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Mangan's NPI, 1720107121, was assigned on March 28, 2007. Dr. Mangan graduated from Lewis Katz School of Medicine in 2005. Dr. Mangan holds California license C163310.

Dr. Mangan's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Mangan's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Mangan is also affiliated with Hillcrest Medical Center. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Mangan to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mangan practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mangan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mangan is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Mangan's licenses on file in 3 states: California, Pennsylvania and Michigan.

Dmand AI lists chronic anemia, chronic leukemia, colorectal cancer, lymphoma and multiple myeloma among the conditions Dr. Mangan treats.

CMS data shows 616 Medicare services from Dr. Mangan across 4 procedure codes in 2024, for 132 Medicare patients. Medicare paid $61,554 for them.

CMS counts 132 Medicare patients who saw Dr. Mangan in 2024. The largest group is 65 to 74, with 60 patients. 70% of them have high blood pressure, and 67% have high cholesterol. 32% are also on Medicaid. Their average risk score is 2.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mangan's median patient age at 63, with 47% women.

In 2024, Dr. Mangan wrote 1,225 Medicare Part D claims for 75 patients. 74% of them were for generic drugs. CMS names the drug for 885 of them, across 36 drugs with 11 or more claims each, at $2,832,423 in total drug cost. In 2023, CMS named 1,005 claims across 42 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Mangan for performance year 2024, reported as part of a group. Dr. Mangan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mangan as offering telehealth.

Dmand AI links 36 papers to Dr. Mangan, published from 2004 to 2024. 2016 was the busiest year, with 4. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Leukemia, Myeloid, Acute. Dr. Mangan has published most often in Leuk Lymphoma. Dr. Mangan's most frequent co-authors are Selina Luger, MD, Alison W. Loren, MD and Elizabeth O. Hexner, MD.

Dmand AI links Dr. Mangan to 2 clinical trials. Conditions studied include Preleukemia and Thrombocythemia, Essential.

CMS Open Payments shows 82 general payments to Dr. Mangan from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 42% of the total. Astellas Pharma US Inc paid the most, $21,746.

Dmand AI lists 1 award for Dr. Mangan, most recently CMS Stage 1 EHR in 2013.

Dr. Mangan graduated from Lewis Katz School of Medicine in 2005. Dr. Mangan is a member of ASCO and ASH.

Dr. Mangan is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.